Given the oncogenic potential of IGF-IR, targeted therapeutic strategies have been explored, including Picropodophyllin (PPP) designed to block IGF-IR activation, has been tested in clinical trials for a range of tumors and has shown significant anti-tumor efficacy (34). This evidence concerns the gene IGF1R and neoplasm.